Blue Shield of California taps Amazon, Mark Cuban’s Cost Plus Drugs for its pharmacy network
Source: Blue Shield of CaliforniaBlue Shield of California is teaming up with Mark Cuban's Cost Plus Drug Company and Amazon ...
Tag: Health care industry
Young people are at risk of harsh respiratory problems after 30 days of e-cigarette use, study says
A man uses a Juul vaporizer in Atlanta, Georgia, Sept. 26, 2019.Elijah Nouvelage | ReutersYoung people are at risk of ...
SEC investigating Illumina over acquisition of cancer test developer Grail
A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021.Mike ...
Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, ...
Beyond Big Tech: Alternative ways to invest in A.I., according to two ETF experts
While ETFs holding stocks such as Microsoft, Tesla and Meta Platforms have outperformed this year, there are other ways to ...
New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here’s why
A pharmacist delivers a COVID-19 booster dose at a Chicago CVS store.Antonio Perez | Tribune News Service | Getty ImagesA ...
Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time
In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San ...
Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
Kenvue, a unit of Johnson & Johnson's consumer health business.CFOTO | Future Publishing | Getty ImagesJohnson & Johnson on Monday ...
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson's consumer-health business, speaks during an interview to celebrate its IPO ...
Eli Lilly expects FDA decision on Alzheimer’s treatment donanemab by the end of the year
Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's treatment, donanemab, ...
